Purdue Pharma has been granted a patent for using tinostamustine in treating T-cell prolymphocytic leukemia (T-PLL). The patent includes a kit with the drug and instructions for administering it at an effective dosage level for T-PLL treatment. GlobalData’s report on Purdue Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Purdue Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Purdue Pharma's grant share as of February 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of t-cell prolymphocytic leukemia using tinostamustine
A recently granted patent (Publication Number: US11918558B2) discloses a kit and pharmaceutical composition for treating T-cell prolymphocytic leukemia (T-PLL). The kit includes tinostamustine or its pharmaceutically acceptable salt in a therapeutically effective amount, along with instructions for administration to patients in need of T-PLL treatment. The dosage level for effective treatment ranges from 0.3 mg/m2 to 300 mg/m2 of the patient's body surface area, providing a specific guideline for healthcare professionals.
Moreover, the pharmaceutical composition described in the patent comprises tinostamustine or its salt in a therapeutically effective amount for treating T-PLL. The dosage level for administration falls within the range of 0.3 mg/m2 to 300 mg/m2 of the patient's body surface area, ensuring the appropriate dosage for effective treatment. Additionally, the composition may include a liquid carrier, specifically polyethylene glycol, and is formulated for intravenous administration, highlighting the specific formulation and route of administration for this innovative treatment option for T-PLL patients.
To know more about GlobalData’s detailed insights on Purdue Pharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.